Department of Psychiatry, Shandong University School of Medicine, Jinan City, Shandong, People's Republic of China.
Department of Psychiatry, Shandong Mental Health Center, Jinan City, Shandong, People's Republic of China.
J Biol Regul Homeost Agents. 2018 Sep-Oct;32(5):1231-1237.
This study aimed to investigate the relationship between sleep disorders and lymphocyte subsets and cytokines in patients with lung cancer undergoing radiotherapy, and to establish a theoretical foundation for predicting sleep disorders and preventing interventions in radiotherapy in lung cancer patients. Ninety-two patients with lung cancer requiring radiotherapy were selected as the study subjects. The patients' demographic data and disease-related conditions were investigated. Their quality of sleep was measured before radiotherapy, after two and four weeks of radiotherapy, and at the end of radiotherapy. According to the Pittsburgh Sleep Quality Index Number Table (PSQI), patients with PSQI score> 7 points were put into a sleep disorder group, and patients with PSQI score 0-7 were put into a normal sleep group. Lymphocyte subsets were enumerated and cytokine levels (IL-6, IL-1b) were measured during these four periods. The difference in sleep disorders at four weeks between patients with or without synchronous chemotherapy was statistically significant (P less than 0.05). The levels of lymphocyte subsets in the sleep disorder group and the control sleep group showed no difference in the index of lymphocyte subsets before radiotherapy. In the sleep disorder group, CD4+ cells were lower after two weeks of radiotherapy (P less than 0.05). After four weeks of radiotherapy, CD3+, CD4+, and CD16+56+ subsets were lower (P less than 0.05). At the end of radiotherapy, there was no difference in each index. There was no significant difference in IL-6 levels between the two groups before radiotherapy, after two weeks, or after four weeks (P greater than 0.05). At the end of radiotherapy, IL-6 levels in the sleep disorder group were higher than those in the control sleep group (P less than 0.05). There was no significant difference in IL-1b between the two groups (P greater than 0.05). In conclusion, monitoring of T-lymphocyte subsets and IL-6 levels in patients is enhanced during radiotherapy. Clinically effective programs of radiotherapy for lung cancer improve the body's immune status.
本研究旨在探讨肺癌放疗患者睡眠障碍与淋巴细胞亚群和细胞因子的关系，为预测肺癌放疗患者睡眠障碍和预防干预提供理论依据。选取 92 例需要放疗的肺癌患者作为研究对象，调查患者的人口统计学资料和疾病相关情况，在放疗前、放疗 2 周和 4 周及放疗结束时测量患者的睡眠质量。根据匹兹堡睡眠质量指数表（PSQI），PSQI 评分>7 分的患者纳入睡眠障碍组，PSQI 评分 0-7 分的患者纳入正常睡眠组。在这四个时期，计数淋巴细胞亚群并测量细胞因子水平（IL-6、IL-1b）。有或无同步化疗的患者在放疗 4 周时睡眠障碍的差异有统计学意义（P<0.05）。在放疗前，睡眠障碍组和对照组的淋巴细胞亚群指标中，淋巴细胞亚群水平无差异。在睡眠障碍组中，放疗后 2 周 CD4+细胞降低（P<0.05）。放疗后 4 周，CD3+、CD4+和 CD16+56+亚群降低（P<0.05）。放疗结束时，各指标无差异。放疗前、放疗 2 周和 4 周两组 IL-6 水平无差异（P>0.05）。放疗结束时，睡眠障碍组 IL-6 水平高于对照组（P<0.05）。两组 IL-1b 无差异（P>0.05）。结论，放疗期间增强对患者 T 淋巴细胞亚群和 IL-6 水平的监测，临床有效的肺癌放疗方案改善机体免疫状态。
